Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia

Version 1 : Received: 3 November 2020 / Approved: 4 November 2020 / Online: 4 November 2020 (12:37:47 CET)

How to cite: Jaluvka, F.; Ihnat, P.; Madaric, J.; Prochazka, V. Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia. Preprints 2020, 2020110193 (doi: 10.20944/preprints202011.0193.v1). Jaluvka, F.; Ihnat, P.; Madaric, J.; Prochazka, V. Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia. Preprints 2020, 2020110193 (doi: 10.20944/preprints202011.0193.v1).

Abstract

Background: The treatment of peripheral arterial disease (PAD) is focused on improving perfusion and oxygenation in the affected limb. Standard revascularization methods include bypass surgery, endovascular interventional procedures, or hybrid revascularization. Cell-based therapy can be an alternative strategy for patients with no-option critical limb ischemia who are not eligible for endovascular or surgical procedures. Aims: This review offers an up-to-date critical overview of the knowledge and data of evidence-based medicine on the position of cell therapy in the treatment of PAD. It provides an overview of current evidence and appraises the future perspectives of cell-based therapy, emphasizing the potential of exosomal cell-free approaches in patients with critical limb ischemia. Results: Meta-analyses focused on cell therapy problems in PAD treatment confirm a significantly greater chance of limb salvage in the first year after the cell therapy administration. The opportunity of defect healing is at least two times higher when compared with the standard conservative therapy. Secondary endpoints of the available meta-analyses are also included in this review. Improvement of perfusion and oxygenation parameters in the affected limb, pain regression, and claudication interval prolongation are discussed. Conclusions: The available evidence-based medicine data show that this technique is safe, associated with minimum complications or adverse events, and effective.

Subject Areas

Cell therapy, Peripheral arterial disease, Bone marrow, Adipose tissue, Mesenchymal stem cells, Exosome, Critical limb ischemia.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.